PHARM Pharming Group NV

Pharming Group to report third quarter 2023 financial results on October 26

Pharming Group to report third quarter 2023 financial results on October 26

Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023.

Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 EDT on October 26, 2023.

To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

Conference call registration:

Please note, the Company will only take questions from dial-in attendees.

To watch the live webcast, please register in advance using the link below.

Webcast registration:

About Pharming Group N.V.

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit and find us on .

For further public information, contact:

Pharming Group, Leiden, The Netherlands

Michael Levitan, VP Investor Relations & Corporate Communications

T: +1 (908) 705 1696

Heather Robertson, Investor Relations & Corporate Communications Manager

E:

FTI Consulting, London, UK

Victoria Foster Mitchell/Alex Shaw/Amy Byrne

T: 0

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands

Leon Melens

T: 27

E:





EN
12/10/2023

Underlying

PHARMPharming Group NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharming Group NV

 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group announces 2026 financial guidance and highlights rare d...

Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)2026 total operating expense guidance of US$330 – US$335 millionInvestor Day will be webcast today starting at 10:00 am EST (16:...

February 3, 2026 1 EN
 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group receives Complete Response Letter from U.S. FDA for sND...

Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rar...

February 1, 2026 1 EN
 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group reports preliminary 2025 revenues and announces Investo...

Pharming Group reports preliminary 2025 revenues and announces Investor Day Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET). Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2...

January 8, 2026 1 EN
Free Trial
PHARM Pharming Group ...

Pharming Group NV: 1 director

A director at Pharming Group NV sold 90,691 shares at 1.500EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

PHARM PHARMING GROUP NV
12/01/25 December 1, 2025 1 EN
 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group reports third quarter 2025 financial results with signi...

Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribersJoenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy FDA granted priority review of sNDA for leniolisib for c...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch